

Carsten Buhmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1696314/publications.pdf>

Version: 2024-02-01

77
papers

2,408
citations

304743

22
h-index

233421

45
g-index

86
all docs

86
docs citations

86
times ranked

2925
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of four lipoprotein classes in human cerebrospinal fluid. <i>Journal of Lipid Research</i> , 2001, 42, 1143-1151.	4.2	243
2	Characterization of four lipoprotein classes in human cerebrospinal fluid. <i>Journal of Lipid Research</i> , 2001, 42, 1143-51.	4.2	191
3	Increased lipoprotein oxidation in alzheimerâ€™s disease. <i>Free Radical Biology and Medicine</i> , 2000, 28, 351-360.	2.9	181
4	Activity Parameters of Subthalamic Nucleus Neurons Selectively Predict Motor Symptom Severity in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2014, 34, 6273-6285.	3.6	157
5	Wearable sensor-based objective assessment of motor symptoms in Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2016, 123, 57-64.	2.8	117
6	Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early Stages: A Prospective Cohort Study. <i>Dysphagia</i> , 2018, 33, 41-50.	1.8	114
7	Phase-Dependent Suppression of Beta Oscillations in Parkinson's Disease Patients. <i>Journal of Neuroscience</i> , 2019, 39, 1119-1134.	3.6	89
8	Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. <i>Neurobiology of Disease</i> , 2004, 15, 160-170.	4.4	88
9	Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. <i>Journal of Neurology</i> , 2017, 264, 758-769.	3.6	74
10	Asymmetric pallidal neuronal activity in patients with cervical dystonia. <i>Frontiers in Systems Neuroscience</i> , 2014, 8, 15.	2.5	59
11	Spatio-temporal dynamics of cortical drive to human subthalamic nucleus neurons in Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 112, 49-62.	4.4	58
12	Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. <i>Movement Disorders</i> , 2003, 18, 219-221.	3.9	54
13	Management of Pain in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, S37-S48.	2.8	38
14	The impact of Parkinson disease on patientsâ€™ sexuality and relationship. <i>Journal of Neural Transmission</i> , 2017, 124, 983-996.	2.8	37
15	Predictive timing functions of cortical beta oscillations are impaired in Parkinson's disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus. <i>NeuroImage: Clinical</i> , 2015, 9, 436-449.	2.7	36
16	Gait Training in Virtual Reality: Short-Term Effects of Different Virtual Manipulation Techniques in Parkinsonâ€™s Disease. <i>Cells</i> , 2019, 8, 419.	4.1	36
17	Thalamic short pulse stimulation diminishes adverse effects in essential tremor patients. <i>Neurology</i> , 2018, 91, e704-e713.	1.1	35
18	Predictive clinical factors for penetration and aspiration in Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13524.	3.0	34

#	ARTICLE	IF	CITATIONS
19	Detection of retinal changes in idiopathic Parkinson's disease using high-resolution optical coherence tomography and heidelberg retina tomography. <i>Acta Ophthalmologica</i> , 2015, 93, e578-84.	1.1	31
20	Increased Lipid Peroxidation in Cerebrospinal Fluid and Plasma from Patients with Creutzfeldt-Jakob Disease. <i>Neurobiology of Disease</i> , 2002, 10, 150-156.	4.4	30
21	Pill swallowing in Parkinson's disease: A prospective study based on flexible endoscopic evaluation of swallowing. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 51-56.	2.2	30
22	Evidence for the use of cannabinoids in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 913-924.	2.8	25
23	Waking up the brain: a case study of stimulation-induced wakeful unawareness during anaesthesia. <i>Progress in Brain Research</i> , 2009, 177, 125-145.	1.4	24
24	Subthalamic deep brain stimulation improves auditory sensory gating deficit in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2015, 126, 565-574.	1.5	24
25	Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice. <i>Journal of Neural Transmission</i> , 2022, 129, 1201-1217.	2.8	23
26	Cannabis in Parkinson's Disease: The Patients' View. <i>Journal of Parkinson's Disease</i> , 2021, 11, 309-321.	2.8	22
27	STN Stimulation in General Anaesthesia: Evidence Beyond Evidence-Based Medicine. , 2013, 117, 19-25.		22
28	Diabetes, Glycated Hemoglobin (<sc>HbA1c</sc>), and Neuroaxonal Damage in Parkinson's Disease (<sc>MARK-EPD Study</sc>). <i>Movement Disorders</i> , 2022, 37, 1299-1304.	3.9	22
29	Scanning laser polarimetry and spectral domain optical coherence tomography for the detection of retinal changes in Parkinson's disease. <i>Acta Ophthalmologica</i> , 2015, 93, e672-7.	1.1	21
30	Drooling is no early sign of dysphagia in Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13259.	3.0	21
31	Specialized Staff for the Care of People with Parkinson's Disease in Germany: An Overview. <i>Journal of Clinical Medicine</i> , 2020, 9, 2581.	2.4	20
32	A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation. <i>Movement Disorders</i> , 2020, 35, 1471-1475.	3.9	20
33	Effect of subthalamic nucleus deep brain stimulation on driving in Parkinson disease. <i>Neurology</i> , 2014, 82, 32-40.	1.1	19
34	Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients. <i>PLoS ONE</i> , 2015, 10, e0135287.	2.5	19
35	Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1863-1868.	3.9	18
36	Visual recovery in a man with the rare combination of mtDNA 11778 LHON mutation and a MS-like disease after mitoxantrone therapy. <i>Acta Neurologica Scandinavica</i> , 2002, 106, 236-239.	2.1	17

#	ARTICLE	IF	CITATIONS
37	Is the Munich dysphagia Test "Parkinson's disease (MDT-PD) a valid screening tool for patients at risk for aspiration?. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 138-143.	2.2	17
38	The challenge of pain in the pharmacological management of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1847-1854.	1.8	16
39	Pallidal lead placement in dystonia: leads of non-responders are contained within an anatomical range defined by responders. <i>Journal of Neurology</i> , 2020, 267, 1663-1671.	3.6	16
40	Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany. <i>Journal of Clinical Medicine</i> , 2020, 9, 1455.	2.4	15
41	Retinal degeneration in progressive supranuclear palsy measured by optical coherence tomography and scanning laser polarimetry. <i>Scientific Reports</i> , 2017, 7, 5357.	3.3	14
42	STN-DBS Reduces Saccadic Hypometria but Not Visuospatial Bias in Parkinson's Disease Patients. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 85.	2.0	12
43	Mapping stimulation-induced beneficial and adverse effects in the subthalamic area of essential tremor patients. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 150-155.	2.2	12
44	Modulation of specific components of sleep disturbances by simultaneous subthalamic and nigral stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 141-147.	2.2	12
45	Short Pulse and Conventional Deep Brain Stimulation Equally Improve the Parkinsonian Gait Disorder. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1455-1464.	2.8	12
46	Altered neural responses to heat pain in drug-naive patients with Parkinson disease. <i>Pain</i> , 2017, 158, 1408-1416.	4.2	11
47	Discussing sexuality with Parkinson's disease patients: a multinational survey among neurologists. <i>Journal of Neural Transmission</i> , 2019, 126, 1273-1280.	2.8	11
48	Pearls & Oysters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy. <i>Neurology</i> , 2018, 90, 482-485.	1.1	10
49	Impact of simultaneous subthalamic and nigral stimulation on dysphagia in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 628-638.	3.7	10
50	Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 5-10.	2.2	10
51	Deep Brain Stimulation of the Ventrolateral Thalamic Base and Posterior Subthalamic Area in Dystonic Head Tremor. <i>Acta Neurochirurgica Supplementum</i> , 2013, 117, 67-72.	1.0	10
52	Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study. <i>Journal of Neural Transmission</i> , 2022, 129, 295-300.	2.8	10
53	Synchronized cortico-subthalamic beta oscillations in Parkin-associated Parkinson's disease. <i>Clinical Neurophysiology</i> , 2015, 126, 2241-2243.	1.5	9
54	The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care. <i>Journal of Neural Transmission</i> , 2018, 125, 1461-1472.	2.8	9

#	ARTICLE	IF	CITATIONS
55	Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (<sc>MARK&PD</sc>). <i>Movement Disorders</i> , 2022, 37, 435-436.	3.9	9
56	Quantitative Sensory Testing (QST) in Drug-Naïve Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 369-378.	2.8	8
57	Sex Disparities in the Self-Evaluation of Subthalamic Deep Brain Stimulation Effects on Mood and Personality in Parkinson's Disease Patients. <i>Frontiers in Neurology</i> , 2020, 11, 776.	2.4	8
58	The ability of the eating assessment tool-10 to detect penetration and aspiration in Parkinson's disease. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 1661-1668.	1.6	8
59	Could deep brain stimulation help with driving for patients with Parkinson's?. <i>Expert Review of Medical Devices</i> , 2014, 11, 427-429.	2.8	7
60	Impact of Combined Subthalamic Nucleus and Substantia Nigra Stimulation on Neuropsychiatric Symptoms in Parkinson's Disease Patients. <i>Parkinson's Disease</i> , 2017, 2017, 1-14.	1.1	7
61	Dysphagia Screening in Parkinson's Disease. A diagnostic accuracy cross-sectional study investigating the applicability of the Gugging Swallowing Screen (GUSS). <i>Neurogastroenterology and Motility</i> , 2021, 33, e14034.	3.0	7
62	Impact of COVID-19 Pandemic on (Health) Care Situation of People with Parkinson's Disease in Germany (Care4PD). <i>Brain Sciences</i> , 2022, 12, 62.	2.3	7
63	Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. <i>Journal of Neural Transmission</i> , 2017, 124, 1005-1013.	2.8	6
64	Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 28-31.	2.2	6
65	Impact of Deep Brain Stimulation on Daily Routine Driving Practice in Patients with Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-9.	1.1	5
66	Stress Management Training (SMT) Improves Coping of Tremor-Boosting Psychosocial Stressors and Depression in Patients with Parkinson's Disease: A Controlled Prospective Study. <i>Parkinson's Disease</i> , 2018, 2018, 1-12.	1.1	5
67	Swallowing speed is no adequate predictor of aspiration in Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13713.	3.0	5
68	Cardiac manifestation is evident in chorea-acanthocytosis but different from McLeod syndrome. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 90-95.	2.2	4
69	Short pulse and directional thalamic deep brain stimulation have differential effects in parkinsonian and essential tremor. <i>Scientific Reports</i> , 2022, 12, 7251.	3.3	4
70	Conditioned pain modulation in drug-naïve patients with de novo Parkinson's disease. <i>Neurological Research and Practice</i> , 2019, 1, 27.	2.0	2
71	Prevalence, clinical presentations and impact on relationship of sexual dysfunction in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2022, 162, 1-19.	2.0	2
72	Levodopa-induced dystonia in a patient with possible progressive supranuclear palsy with progressive gait freezing. <i>Journal of the Neurological Sciences</i> , 2018, 388, 139-140.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Nine-years follow-up of cavernoma located in basal ganglia mimicking Parkinson's disease. Clinical Neurology and Neurosurgery, 2020, 190, 105664.	1.4	1
74	Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease". Movement Disorders, 2021, 36, 273-274.	3.9	1
75	Comparison of Montreal cognitive assessment and Mattis dementia rating scale in the preoperative evaluation of subthalamic stimulation in Parkinson's disease. PLoS ONE, 2022, 17, e0265314.	2.5	1
76	Reply to: "Terminal Pro-B-type Natriuretic Peptide Levels in Parkinson's Disease". Movement Disorders, 2020, 35, 1888-1888.	3.9	0
77	F28...Novel mutations and findings in a cohort of McLeod neuroacanthocytosis, an X-linked HD phenocopy. , 2021, , .		0